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Summary-Results with cyclical combination chemotherapy in advanced breast
cancer are presented. The overall remission rate, 79 per cent, is superior to that
obtained by two conventional endocrine procedures, administration of norethisterone
acetate and hypophysectomy. The advantage is especially pronounced in patients
with visceral deposits.
SYSTEMIC treatment occupies an
important position in the management of
certain advanced cancers. In breast can-
cer endocrine measures have traditionally
held pride of place though more recently
cytotoxic drugs have attracted interest.
Generally, 20-30 per cent ofpatients show
a response of 6-8 months' duration with
either technique. The next step, as fore-
shadowed by Elion, Singer and Hitchings
(1954) and Goldin and Mantel (1957), was
the use of cytotoxic drugs in combination,
and in breast cancer Hurley et al. (1960),
Greenspan (1966), and Cooper (1969)
obtained encouraging results, although
Horton and his co-workers (1967) were
not so impressed. The small numbers of
patients reported require confirmation
and the relationship of the results to
certain characteristics of cancer of the
breast remains unexplored. Accordingly,
in 1970 a clinical investigation of cyclical
combination chemotherapy (CCC) was
started in established late cancers of all
types. By June 1, 1973, 400 patients had
been admitted to the programme, the
breast cancer group numbering 81; these
latter are reported in this paper. For
comparison, and especially to show the
relationship between response to treat-
ment and individual characteristics of the
neoplasm, studies by the first author with
hypophysectomy and norethisterone ace-
tate (NEA) (SH 420, Schering Chemicals)
are quoted (Edelstyn et al., 1958; Edel-
styn, Gleadhill and Lyons, 1968; Edel-
styn, 1973). As the criteria for patient
inclusion and assessment were identical
and carried out in the sameunit, we believe
this comparison to be of value.
MATERIALS AND METHODS
The criteria for patient inclusion were
that they all had evidence of progressive
locally recurrent or metastatic breast cancer,
in every instance beyond cure by local treat-
ment.
The therapeutic procedures were (a)
hypophysectomy performed by combined
transfrontal removal of the pituitary with
insertion of a plug of 90Y, a procedure
developed to destroy residual fragments of
gland (Edelstyn et al., 1958); (b) NEA
administered orally, 10 mg 4 times daily
(Edelstyn, 1973); (c) CCC regimen given as
follows: Endoxana, 500 mg i.v. on Days 1 and
7, vincristine 0 75 mg i.v., 5-fluorouracil 500
mg i.v., methotrexate 2-5 mg b.d. orally,
given on Days 2 to 6 inclusive.
After 5 clear weeks the course was
repeatedandthis pattern was continuedfor as
long as it was ofvalue.
Definition of response.-Objective im-
provement of at least 50 per cent in demon-
strable lesions except bony deposits, where
arrest of existing disease with pronounced
subjective benefit is considered to be a
response. Justification for this exception
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was considered to be the common and lasting
relief of bone pain, which occurs in the
absence ofradiologically demonstrable repair.
The criterion of a minimum of 10 weeks sus-
tained response is required and when
deterioration in any lesion or new deposits
appeared the response was considered nega-
tive.
Side-effects-With hypophysectomy the
most serious complication was visual dam-
age; with NEA occasional gastrointestinal
disturbance was noted and with CCC the
commonest complication was alopecia. Bone
marrow depression has been occasionally
fatal. Stomatitis was uncommon. The
principal gastrointestinal problem was con-
stipation, which in 3 patients produced a
temporary intestinal obstruction. Peripheral
neuritis was rarely of significance. Two
deaths occurred inexplicably in apparently
well patients after their discharge.
Treatment deaths. For hypophysectomy,
death within one month of operation was
considered to be due to the procedure.
There were 10 instanees. With NEA there
were no deaths and with CCC, as treatment
courses are continued until it is apparent that
response is improbable or, if gained has been
lost, death would often occur from natural
causes within one month of cessation of
therapy. ' Treatment death" is defined as
fatality directly attributable to this pro-
cedure. Eight patieits (10 per cent) are
included in this group.
RESULTS
Overall results
A total of 154 patients were included
in the NEA study, 102 in the hypophy-
sectomy investigation and 81 who were
given CCC. Results ofthe treatments are
summarized in the Table.
In interpreting these data, it is im-
portant to bear in mind that the results
from 3 separate studies must be compared
cautiously. Whilst selection and assess-
ment criteria were similar, the ultimate
test must be confirmation by others.
Comparison of the total percentage res-
ponse between the CCC and hypophy-
sectomy studies yields x2 -13 18, d.f.
1, P < 0 001 and for percentage response
of those assessable x2 = 16 41, d.f. - 1,
P < 0 001 both figures showing a real
difference in efficacy.
Individual characteristics of the disease
It has been shown (Edelstyn et al.,
1968) that certain clinical factors can assist
in selecting patients for endocrine therapy.
Thus with a predominantly local recur-
rence NEA is optimal, if bony, hypophy-
sectomy is the treatment of choice and
when visceral none of these measures is of
value.
The time lapse between treating the
primary and recognition of recurrence
(" disease free interval ") when less than
24 months, is unfavourable for endocrine
therapy, as is age under 55 years for NEA,
and 45 for hypophysectomy. Where 2 or
3 such factors are unfavourable, the
probability of response is virtually zero.
For CCC a much less marked trend was
noted, reponse rates ranging from 100 per
cent, all factors being favourable, to 70 per
cent when all three factors were unfavour-
able. This effect appears to be due
mainly to the fact that patients with
visceral metastases show a 75 per cent
response compared with the 95 per cent
response found in other categories.
DISCUSSION
This report suggests that combination
chemotherapy has much to offer in
advanced breast cancer. It is the first
approach consistently benefiting visceral
metastases, a finding confirmed by Green-
TABLE. Overall Response to Treatment in the Three Studies
Response percentage ± s.e.
Total patients Assessable patients
33-8±3-8 41-644
52-0±4-9 5764-5-2
79*0-44-5 87-743-8
Treatment
NEA
Hyp.
CCC
Total
154
102
81
Assessable
125
92
73
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span (1966, 1972), Cooper (1969), Shingle-
ton, Sedransk and Johnson (1971), Han-
ham, Newton and Westbury (1971), and
Ansfield et al. (1971). It is of value no
matter the age, speed of disease progres-
sion or recurrence pattern.
Thus it is considered that for the first
time a systemic therapy is available which
is effective in all clinical types ofadvanced
breast cancer. The implications for endo-
crine management are considerable and it
wouwd appear that the traditional meas-
ures may have little further part to play,
except norethisterone acetate for slowly
progressive local disease in the older
woman, and possibly hypophysectomy for
bone metastases in similar circumstances.
While most encouraging, many prob-
lems remain to be resolved before CCC can
be applied in the most effective manner to
a wider section of patients with breast
cancer.
We are now at the stage where alterna-
tive cytotoxic regimens can begin to be
compared, in order to determine optimal
agents, doses and timing ofadministration
for breast cancer and indeed for other solid
tumours. A primary aim of such alterna-
tives is reduction in toxicity as well as
increasedtherapeuticefficacy. Anequally
important consideration is to minimize
the discomfort and inconvenience for the
patient by attempting to develop drug
combinations which require less time and
fewer injections.
More controversially, there arises the
problem of the stage in disease evolution
at which therapy should be offered. With
reduced toxicity and easier administra-
tion the choice of whether combination
chemotherapy will be delayed until local
treatments have patently failed, or
whether it has a useful role at an earlier
stage will have to be decided.
A " fall back " regimen for patients
either not responding initially or sub-
sequently escaping control has been de-
vised. This incorporates bleomycin and
CCNU in addition to the agents already
employed. Preliminary results show 4
responses amongst 11 patients.
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